Royalty Pharma plc logo

Royalty Pharma plc (RPRX) Financials

NASDAQ NASDAQ:RPRX

Market Cap

12.31B

Total Revenue

2.24B

Gross Profit

2.23B

Operating Income

977.50M

Net Income

42.83M

Metric201720182019202020212022
1,597,930,0001,794,894,0001,814,254,0002,122,000,0002,289,463,0002,237,215,000
--135,960,000--88,111,00022,996,0005,670,000
1,597,930,0001,658,934,0001,814,254,0002,033,889,0002,266,467,0002,231,545,000
117,866,000392,609,00083,036,00026,000,000200,084,000177,106,000
------------
106,440,00061,906,000103,439,000182,000,000182,826,000227,303,000
106,440,00061,906,000103,439,000182,000,000182,826,000227,303,000
658,238,000430,448,000-808,922,000527,000,000858,748,0001,314,323,000
939,692,0001,364,446,0002,623,176,0001,595,000,0001,430,715,000977,499,000
644,065,000408,924,000-161,757,000107,000,000-189,514,000-747,435,000
1,141,882,0001,413,613,0002,637,305,0001,882,000,0001,482,078,000983,169,000
33,267,00033,267,00014,129,000287,000,00051,363,0005,670,000
6,762,00024,441,00022,329,00028,379,00053,535,00078,335,000
247,339,000279,956,000268,573,000157,000,000166,142,000187,961,000
1,343,180,0001,517,855,0002,461,419,0001,702,000,0001,241,201,000230,064,000
542,655,000433,365,000349,333,0001,147,000,000762,447,000187,232,000
1,210,025,0001,377,729,0002,348,535,000555,000,000478,754,00042,832,000
3.423.896.631.481.150.098
3.423.896.631.481.150.098
354,175,555354,175,555354,175,555375,444,000414,794,000437,963,000
354,175,555354,175,555354,175,555375,455,000414,802,000437,972,000
658,238,000430,448,000-808,922,000527,000,000858,748,0001,314,323,000
-1,618,000-1,518,000-995,397,000319,000,000475,838,000909,914,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

New York, NY, US

CEO

Mr. Pablo Gerardo Legorreta

Employees

--

About the Company

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.